VERIGRAFT generates personalized tissue-engineered transplants for use in regenerative medicine. The company’s unique technology platform turns donated allogeneic (“foreign”) tissue into an autologous-like (“personalized”) tissue and thus avoids transplant rejection and the need for life-long immunosuppression. Donated, allogenic tissue is patient-individualized by a combination of DC (Decellularization) and RC (Reconditioning/Recellularization) processes. VERIGRAFT’s development pipeline comprises products in the areas of vascular regeneration as well as peripheral nerve repair.
Donated blood vessels that serve as a starting point are obtained from deceased organ donors. The DC process uses multiple cycles with specifically developed reagents to gently remove donor cells and DNA. This results in a clean extracellular matrix scaffold which has been depleted of immunogenic cellular material that would evoke an adverse immune response in the recipient. At the same time the important three-dimensional structural properties as well as the mechanical strength and functionality of the tissue have been preserved.
The patented RC process is based on a small (25-50 ml) sample of the patient’s own peripheral blood which is supplemented with growth factors, nutrients and balancing agents. The resulting culture medium is used for the perfusion culture of the cell free scaffold which leads to reconditioning and repopulation of the tissue by cells and other biological components from the patient’s blood. In this way the engineered blood vessel becomes like the patient’s own, and the risk for thrombosis and infection is greatly reduced compared to synthetic grafts. It has also been shown that such tissue engineered products do not trigger the recipient’s immune system.
The fact that the patient’s blood is used directly, without artificially selecting or expanding cells in the lab, contributes favorably to the product’s safety profile.
“VERIGRAFT’s technology can offer a wide range of potential applications in transplantation“
The unique and ground-breaking solution provided by VERIGRAFT can avoid the complications and adverse consequences of many traditional treatments, thus leading to a generally improved quality of life. Examples for complications and adverse consequences are, the need for repeated surgery if e.g. synthetic material is transplanted (short life-span of the synthetic vessel), the risk for severe infections of e.g. synthetic grafts, as the patient’s immune defense is not effective in such no-biological materials or the need for life-long immunosuppressive drugs to avoid transplant rejection if e.g. a vessel from a donor is used directly. Immunosuppressive drugs, typically imply severe side effects such as frequent infections as well as damage to vital organs like livers, lungs, kidneys etc. Furthermore, using such life-long drugs is typically associated with a higher risk for developing cancer.